- Home
- ORGS
ORGS
Orgenesis Inc.
as 05-20-2024 2:33pm EST
$.
+$.
+.%
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | GERMANTOWN |
| Market Cap: | 19.0M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 184.5K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.91 | EPS Growth: | 223.73 |
| 52 Week Low/High: | $0.25 - $1.50 | Next Earning Date: | 05-28-2024 |
| Revenue: | $530,000 | Revenue Growth: | -98.53% |
| Revenue Growth (this year): | 13429.43% | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Orgenesis Inc. (ORGS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Safier Jacob | ORGS | 10% Owner | Feb 1 '24 | Buy | $0.33 | 10,100 | $3,331.99 | 3,110,100 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.67 | 5,000 | $3,344.50 | 2,739,860 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.69 | 100,000 | $68,950.00 | 2,839,860 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.67 | 25,000 | $16,780.00 | 2,864,860 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.80 | 10,000 | $8,030.00 | 2,874,860 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.93 | 5,100 | $4,730.76 | 2,879,960 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.86 | 603 | $519.06 | 2,880,563 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.90 | 10,000 | $8,999.00 | 2,890,563 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.88 | 500 | $437.60 | 2,891,063 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.93 | 500 | $465.25 | 2,891,563 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.74 | 5,000 | $3,690.50 | 2,896,563 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.81 | 3,437 | $2,768.85 | 2,900,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.84 | 20,000 | $16,888.00 | 2,920,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.71 | 20,000 | $14,188.00 | 2,940,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.65 | 20,000 | $13,054.00 | 2,960,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.58 | 1,184 | $687.67 | 2,961,184 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.51 | 5,800 | $2,958.58 | 2,966,984 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.54 | 5,000 | $2,701.00 | 2,971,984 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.46 | 1,016 | $466.85 | 2,973,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.53 | 2,000 | $1,061.80 | 2,975,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.54 | 3,000 | $1,626.30 | 2,978,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.45 | 10,000 | $4,483.00 | 2,988,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.37 | 10,000 | $3,690.00 | 2,998,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.33 | 2,000 | $659.40 | 3,000,000 | SEC Form 4 |
| Safier Jacob | ORGS | 10% Owner | Sep 7 '23 | Buy | $0.33 | 10,000 | $3,309.00 | 3,010,000 | SEC Form 4 |
Latest Orgenesis Inc. News
ORGS Breaking Stock News: Dive into ORGS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Orgenesis Provides Year End Business Update
GlobeNewswire
a month ago
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
GlobeNewswire
2 months ago
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
GlobeNewswire
2 months ago
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
GlobeNewswire
3 months ago
Orgenesis Inc. Announces $2.3 Million Private Placement
GlobeNewswire
3 months ago
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
Benzinga
4 months ago
EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic
GlobeNewswire
4 months ago